Masimo Names Former Edwards Critical Care Leader Katie Szyman as CEO

Masimo has announced that Katie Szyman was appointed as the company’s next CEO. Interim CEO Michelle Brennan was named chairman of Masimo’s board and lead independent director Quentin Koffey has been appointed vice chairman.

All of these changes will take place on February 12, 2025.

Szyman’s hiring follows a tumultuous year for Masimo. Founder and CEO Joe Kiani informed the board of his choice to resign as CEO in September 2024 after a shareholder vote removed him from the role of board chair, following a long proxy battle between the company and Politan Capital Management.

Szyman is presently worldwide president of Advanced Patient Monitoring at BD. She previously led the Critical Care business at Edwards Lifesciences, which was acquired in a transaction by BD that closed in September of 2024.

While at Edwards, Szyman accelerated growth in the Critical Care business by entering adjacent markets through internal and external innovation and introducing the first AI technology cleared by the U.S. Food and Drug Administration (FDA) in the patient monitoring space.

She also serves on the board of Inari Medical, which is the subject of an acquisition deal by Stryker that was announced earlier this month.

“I have long admired Masimo as an innovation leader, and I could not be more excited about the opportunity to grow the business and deliver improved outcomes for millions more patients around the world,” said Szyman. “I believe Masimo’s leadership team and bench of talent is top tier, and I am thrilled by the chance to work with and learn from this group.”

“We wanted our next CEO to be someone who is passionate about the role and inspiring as well as engaging the team at Masimo—and Katie made clear that she is that person,” said interim CEO Brennan. “Her advanced patient monitoring category knowledge and deep existing relationships within the industry position her to make an immediate impact as she works with the Board on prioritizing our pipeline to focus on large opportunities, while developing a clear strategy for bringing our next generation patient monitoring platform to market.”

“Katie’s more than 35 years of relevant experience and her unique mix of expertise set her apart during our search and make her an ideal fit to lead the next innovation-focused stage of Masimo’s evolution,” said Quentin Koffey. We also want to thank Michelle for her exemplary performance in the interim CEO role, particularly in leading a seamless transition for customers, employees and shareholders from day one. We look forward to continuing to benefit from her experience and judgment as she moves into her new position as Chairman of the Board.”